Eli Lilly (LLY) EBIAT (2016 - 2025)
Historic EBIAT for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $6.6 billion.
- Eli Lilly's EBIAT rose 5052.16% to $6.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $20.6 billion, marking a year-over-year increase of 9490.08%. This contributed to the annual value of $20.6 billion for FY2025, which is 9490.08% up from last year.
- Per Eli Lilly's latest filing, its EBIAT stood at $6.6 billion for Q4 2025, which was up 5052.16% from $5.6 billion recorded in Q3 2025.
- In the past 5 years, Eli Lilly's EBIAT registered a high of $6.6 billion during Q4 2025, and its lowest value of -$57.4 million during Q3 2023.
- Its 5-year average for EBIAT is $2.4 billion, with a median of $1.8 billion in 2022.
- Its EBIAT has fluctuated over the past 5 years, first plummeted by 10395.4% in 2023, then surged by 179041.81% in 2024.
- Eli Lilly's EBIAT (Quarter) stood at $1.7 billion in 2021, then rose by 12.26% to $1.9 billion in 2022, then rose by 12.98% to $2.2 billion in 2023, then soared by 101.43% to $4.4 billion in 2024, then skyrocketed by 50.52% to $6.6 billion in 2025.
- Its last three reported values are $6.6 billion in Q4 2025, $5.6 billion for Q3 2025, and $5.7 billion during Q2 2025.